Translational & Precision Medicine (TPM) Network

Network Goals

Scientific Expertise:

The Translational & Precision Medicine (TPM) Network and associated Communities facilitate interactions among experts across multidisciplinary fields to foster translational science with a focus on individuals via patient care and society via healthcare. The interactions are through social media, email blasts, and teleconferences with focused scientific content.

Catalyst for Innovation:

The TPM Network is a catalyst for innovation by sponsoring a range of scientific programs at the Annual Meeting focused on translational and precision medicine.

Influence and Impact:

The TPM Network is the lead group engaged in translational and precision medicine and optimal pharmacotherapy in patient care.

Education and Communication:

The TPM Network offers educational opportunities via the Communities.

Organizational Effectiveness:

Leadership within TPM is expanded by a Network Steering Committee.
The TPM Network has regularly scheduled teleconferences and utilizes social media to engage members throughout the year.
The TPM Network fosters the career of its members by assisting Communities in recognizing members for individual achievements and contributions to ASCPT, sponsoring educational programming in translational and precision medicine, and providing opportunities for networking activities throughout an individual’s career.

ASCPT Early Career (EC) Community and Oncology (ONC) Community Members-Only Webinar:
Title: Translational and Clinical Pharmacology Considerations in the Development of Immune-Oncology Drugs
Date and Time: Friday, August 28, 2020, 2:00 pm ET
Speaker: Sree Kasichayanula, PhD
Moderators: Pooja Manchandani, PhD, and Malek Okour, PhD
Description: The presentation will highlight the hallmarks of immuno-oncology drug development and expand on pharmacometrics, clinical pharmacology and statistical strategies to optimize clinical trial design and development of immune-oncology drugs. This will be the first webinar of a three-part series on immune-oncology drug development. Highlights of this session will include:

Fundamental biology underpinnings and trajectory of immune-oncology drug development and how this differs from the standard clinical development paradigm in oncology.
Role and impact of clinical pharmacology aspects to support immune-oncology drug development for monotherapy and combination.
Modeling and simulation strategies and clinical trial designs for early development and pivotal trials.

Registration Link: https://us02web.zoom.us/webinar/register/WN_LHbb5WQqQfeRoRDSW8wwTg

ASCPT Early Development & Drug Safety (EDDS) and Oncology (ONC) Communities Members-Only Webinar
Title: Using Preclinical Data in Phase I Oncology Trials: A Bayesian Decision-Theoretic Approach
Date and Time: Tuesday, September 1, 2020, 11:00 AM ET
Speaker: Haiyan Zheng, PhD
Moderator: Huiming Xia, MSc, PhD
Description: Using preclinical data to specify a prior for the human dose-toxicity model parameter(s) can improve interim dose recommendations and precision for estimating the maximum tolerated dose (MTD). Such advantages, however, must be balanced against the risk that more patients will possibly be treated with excessively toxic doses in the case of a prior-data conflict. This presentation will make a proposal for how to measure and address a prior-data conflict in a sequential study with a small sample size. For learning objectives and additional description information, please click the registration link below.
Registration Link: https://us02web.zoom.us/webinar/register/WN_Uw-PHaVcRnuDTZwa1AfNiw

ASCPT Members-Only Webinar presented by the Infectious Diseases (INF) and Oncology (ONC) Communities
Title: Convergence of Therapeutic Approaches in Oncology and HIV to Target Immune Evasion: Integrating Clinical Pharmacology Lessons Learned
Date and Time: Friday, September 25, 2020, 12:00 pm ET
Speakers: Akintunde Bello, PhD, and Islam Younis, PhD
Moderators: Daria Stypinski, PhD, and Mark Dresser, PhD
Description: This special virtual session will bring together experts with experience in immuno-oncology and HIV research. They will address the major lessons learned from each therapeutic area and the goal to accelerate the pace and lesson the challenges of drug development. The participants will gain knowledge in the overlapping mechanisms in HIV and cancer that have made similar treatment strategies possible. Lessons learned will be shared from HIV combination therapy approaches on establishing contributions of regiment components to overall safety and efficacy. Immuno-oncology on dose-optimization challenges in the development of immune checkpoint inhibitors will also be explored.
Registration Link: https://us02web.zoom.us/webinar/register/WN_kkLBLp9nT26MkB_rW89UXQ